Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.86 - $1.63 $110,596 - $209,618
-128,600 Reduced 62.4%
77,500 $79,000
Q1 2024

May 15, 2024

BUY
$1.27 - $2.24 $127,000 - $224,000
100,000 Added 94.25%
206,100 $377,000
Q4 2023

Feb 14, 2024

BUY
$0.8 - $1.28 $42,320 - $67,712
52,900 Added 99.44%
106,100 $131,000
Q3 2023

Nov 14, 2023

BUY
$0.87 - $1.84 $13,311 - $28,152
15,300 Added 40.37%
53,200 $60,000
Q2 2023

Aug 14, 2023

BUY
$0.51 - $1.43 $102 - $286
200 Added 0.53%
37,900 $34,000
Q1 2023

May 15, 2023

BUY
$0.56 - $1.15 $10,472 - $21,505
18,700 Added 98.42%
37,700 $21,000
Q4 2022

Feb 14, 2023

SELL
$0.25 - $0.58 $3,375 - $7,829
-13,500 Reduced 41.54%
19,000 $11,000
Q3 2022

Nov 14, 2022

BUY
$0.3 - $0.46 $1,920 - $2,944
6,400 Added 24.52%
32,500 $10,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $366M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.